Advertisement

Cardiovascular Issues

  • Michael S. Ewer
Chapter
Part of the MD Anderson Cancer Care Series book series (MDCCS)

Abstract

Modern therapies for cancer are allowing increasing numbers of patients to enjoy long-term remission or cure of their disease. Unfortunately, the very modalities that help achieve these results cause injury to tissues or organs; these injuries may not be transient and may persist for the duration of survivorship. The heart, as a post-mitotic organ, does not regenerate after injury, and therefore is especially vulnerable to the long-term effects of a variety of treatment strategies for cancer. Although the future holds promise that new initiatives will allow organ or tissue regeneration, at present we must maximize protection of the heart at the time of exposure and minimize sequential stresses that might add to the cardiac burden during the period following the toxic injury. We now understand that cardiac injury may follow some forms of chemotherapy and biologic therapy as well as radiation therapy, and oncologists have learned to protect the heart to minimize the immediate damage. The burden of managing residual cardiac injury, however, migrates to the physician who provides care to cancer survivors, so that the late effects of treatment may be minimized. This chapter explores some of the strategies intended to improve quality of life for patients whose initial treatment for cancer resulted in cardiac injury.

Keywords

Cancer Survivor Cardiac Injury Contractile Dysfunction Cardiac Damage Cardiac Stress 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Readings

  1. Cardinale D, Colombo A, Sandri M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–2481.PubMedCrossRefGoogle Scholar
  2. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010(10):564–575.CrossRefGoogle Scholar
  3. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49:1486–1493.PubMedCrossRefGoogle Scholar
  5. Ritchie J, Singer J, Thorning D. Anthracycline cardiotoxicity: clinical and pathological outcome assessed by radionuclide ejection fraction. Cancer 1970;46:1109–1116.CrossRefGoogle Scholar
  6. Romond EH, Jeong H-H, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30(31):3792–3799.PubMedCrossRefPubMedCentralGoogle Scholar
  7. Schwefer M, Aschenbach R, Heidemann J, Mey C, Lapp H. Constrictive pericarditis, still a diagnostic challenge: comprehensive review of clinical management. Eur J Cardiothorac Surg 2009;36:502–510.PubMedCrossRefGoogle Scholar
  8. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010;28:1308–1315.PubMedCrossRefGoogle Scholar
  9. Wang W, Wainstein R, Freixa X, Dzavik V, Fyles A. Quantitative coronary angiography findings of patients who received previous breast radiotherapy. Radiother Oncol 2011;100(2):184–188.PubMedCrossRefGoogle Scholar

Copyright information

© The University of Texas M. D. Anderson Cancer Center 2015

Authors and Affiliations

  • Michael S. Ewer
    • 1
  1. 1.Department of CardiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations